We focused on the analysis of BRAF V600E, KRAS G12D, KRAS G12V and PIK3CA H1047R because these are known drivers of lung cancer [29] and resistance to EGFR-targeted therapies [17, 23, 24] for which ACB-PCR assays were available [34]. This evidence concerns the gene EGFR and lung cancer.